Repligen Q3 revenue beats estimates on higher demand; lifts outlook
RGEN•Repligen's third-quarter revenue rose 11% to $209 million, beating the $206.62 million analyst estimate, while adjusted EPS of $0.53 topped the $0.46 estimate. The company raised fiscal 2026 revenue guidance to $844 million-$852 million and forecast adjusted EPS of $2.05-$2.09.
1. Quarterly results
Repligen said third-quarter revenue rose 11% to $209 million, above the $206.62 million analyst estimate. Adjusted EPS was $0.53, compared with the $0.46 estimate; adjusted operating income was $33.30 million.
2. Raised outlook
The company raised fiscal 2026 revenue guidance to $844 million-$852 million, representing growth of 14.5%-15.5%, and expects organic revenue growth of 12%-13%. It forecast adjusted EPS of $2.05-$2.09 for the year.
3. Demand and acquisition
Repligen said growth was driven by strength across its diversified portfolio and improving end-market demand, including healthy trends in consumables and services and a growing capital equipment order book. It also said it closed its acquisition of BioLife, which it said strengthens its position in the cell therapy market and expands its portfolio.
